GLUT1 DS
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 248 | グルコーストランスポーター1欠損症 | 15 |
248. グルコーストランスポーター1欠損症
臨床試験数 : 29 / 薬物数 : 9 - (DrugBank : 1) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0
Showing 1 to 10 of 15 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03773770 (ClinicalTrials.gov) | August 1, 201920190801 | 10/12/201820181210 | Expanded Access to Triheptanoin | An Open-label Intermediate-size Treatment Protocol for the Urgent Treatment of Seriously Ill Patients With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) With Triheptanoin (UX007) An Open-label Intermediate-size Treatment Protocol for the Urgent Treatment of Seriously Ill Patient ... | Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | Drug: Triheptanoin | Ultragenyx Pharmaceutical Inc | NULL | Available | N/A | N/A | All | NULL | ||
| 2 | EUCTR2015-005536-17-GB (EUCTR) | 04/08/201720170804 | 11/07/201720170711 | A trial to assess the safety and efficacy of UX007 in patients with movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) A trial to assess the safety and efficacy of UX007 in patients with movement disorders associated wi ... | A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and ... | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 20.0;Level: LLT;Classification code 10061032;Term: Carbohydrate transport disorder;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Glucose Transporter Type 1 deficiency syndrome MedDRA version: 20.0;Level: LLT;Classification code 1 ... | Product Name: UX007 Product Code: UX007 INN or Proposed INN: Not available Other descriptive name: TRIHEPTANOIN Product Name: UX007 Product Code: UX007 INN or Proposed INN: Not available Other descriptive name: TRIH ... | Ultragenyx Pharmaceutical Inc | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | France;United States;Spain;Australia;Israel;Germany;Italy;United Kingdom | ||
| 3 | EUCTR2015-005536-17-FR (EUCTR) | 30/06/201720170630 | 16/05/201720170516 | A trial to assess the safety and efficacy of UX007 in patients with movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) A trial to assess the safety and efficacy of UX007 in patients with movement disorders associated wi ... | A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and ... | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 20.0;Level: LLT;Classification code 10061032;Term: Carbohydrate transport disorder;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Glucose Transporter Type 1 deficiency syndrome MedDRA version: 20.0;Level: LLT;Classification code 1 ... | Product Name: UX007 Product Code: UX007 INN or Proposed INN: Not available Other descriptive name: TRIHEPTANOIN Product Name: UX007 Product Code: UX007 INN or Proposed INN: Not available Other descriptive name: TRIH ... | Ultragenyx Pharmaceutical Inc | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | United States;France;Spain;Ireland;Australia;Israel;Netherlands;Germany;Italy;United Kingdom | ||
| 4 | EUCTR2013-003771-35-DK (EUCTR) | 07/06/201720170607 | 11/04/201720170411 | A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Defic ... | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Effica ... | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 20.0;Level: LLT;Classification code 10061032;Term: Carbohydrate transport disorder;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Glucose Transporter Type 1 deficiency syndrome MedDRA version: 20.0;Level: LLT;Classification code 1 ... | Product Name: Triheptanoin Product Code: UX007 INN or Proposed INN: Not available Other descriptive name: TRIHEPTANOIN Product Name: Triheptanoin Product Code: UX007 INN or Proposed INN: Not available Other descriptive nam ... | Ultragenyx Pharmaceutical Inc | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | France;United States;Hungary;Spain;Australia;Denmark;Israel;Italy;United Kingdom | ||
| 5 | EUCTR2015-005536-17-DE (EUCTR) | 17/05/201720170517 | 01/03/201720170301 | A trial to assess the safety and efficacy of UX007 in patients with movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) A trial to assess the safety and efficacy of UX007 in patients with movement disorders associated wi ... | A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and ... | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 20.0;Level: LLT;Classification code 10061032;Term: Carbohydrate transport disorder;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Glucose Transporter Type 1 deficiency syndrome MedDRA version: 20.0;Level: LLT;Classification code 1 ... | Product Name: UX007 Product Code: UX007 INN or Proposed INN: Not available Other descriptive name: TRIHEPTANOIN Product Name: UX007 Product Code: UX007 INN or Proposed INN: Not available Other descriptive name: TRIH ... | Ultragenyx Pharmaceutical Inc | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | France;United States;Spain;Australia;Israel;Germany;Italy;United Kingdom | ||
| 6 | NCT02960217 (ClinicalTrials.gov) | April 19, 201720170419 | 7/11/201620161107 | Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders As ... | A Phase 3, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) A Phase 3, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy and ... | Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | Drug: UX007;Drug: Placebo | Ultragenyx Pharmaceutical Inc | NULL | Terminated | 6 Years | N/A | All | 44 | Phase 3 | United States;France;Germany;Italy;Spain;United Kingdom;Israel |
| 7 | EUCTR2015-005536-17-ES (EUCTR) | 17/03/201720170317 | 10/03/201720170310 | A trial to assess the safety and efficacy of UX007 in patients with movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) A trial to assess the safety and efficacy of UX007 in patients with movement disorders associated wi ... | A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and ... | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 19.1;Level: LLT;Classification code 10061032;Term: Carbohydrate transport disorder;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Glucose Transporter Type 1 deficiency syndrome MedDRA version: 19.1;Level: LLT;Classification code 1 ... | Product Name: UX007 Product Code: UX007 INN or Proposed INN: Not available Other descriptive name: TRIHEPTANOIN Product Name: UX007 Product Code: UX007 INN or Proposed INN: Not available Other descriptive name: TRIH ... | Ultragenyx Pharmaceutical Inc | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | France;United States;Spain;Ireland;Australia;Israel;Netherlands;Germany;Italy;United Kingdom | ||
| 8 | EUCTR2013-003771-35-ES (EUCTR) | 19/11/201520151119 | 10/08/201520150810 | A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Defic ... | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Effica ... | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 18.0;Level: HLGT;Classification code 10039911;Term: Seizures (incl subtypes);System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Glucose Transporter Type 1 deficiency syndrome MedDRA version: 18.0;Level: HLGT;Classification code ... | Product Name: Triheptanoin / Triheptanoina Product Code: UX007 INN or Proposed INN: Not available Other descriptive name: TRIHEPTANOIN Product Name: Triheptanoin / Triheptanoina Product Code: UX007 INN or Proposed INN: Not available Other ... | Ultragenyx Pharmaceutical Inc | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | France;United States;Hungary;Spain;Denmark;Italy;United Kingdom | ||
| 9 | NCT02599961 (ClinicalTrials.gov) | September 10, 201520150910 | 3/11/201520151103 | Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS) Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Defic ... | An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency Syndrome An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects With ... | Glucose Transporter Type 1 Deficiency Syndrome | Drug: UX007 | Ultragenyx Pharmaceutical Inc | NULL | Terminated | 1 Year | N/A | All | 15 | Phase 2 | United States;Australia;Denmark;Spain;United Kingdom |
| 10 | EUCTR2013-003771-35-GB (EUCTR) | 19/03/201520150319 | 10/11/201420141110 | A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Defic ... | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Effica ... | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 17.1;Level: HLGT;Classification code 10039911;Term: Seizures (incl subtypes);System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Glucose Transporter Type 1 deficiency syndrome MedDRA version: 17.1;Level: HLGT;Classification code ... | Product Name: Triheptanoin Product Code: UX007 INN or Proposed INN: Not available Other descriptive name: TRIHEPTANOIN Product Name: Triheptanoin Product Code: UX007 INN or Proposed INN: Not available Other descriptive nam ... | Ultragenyx Pharmaceutical Inc | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | France;United States;Hungary;Spain;Denmark;Italy;United Kingdom |